Main Session
Sep
30
SH 09 - Lung Cancer/Thoracic Malignancies - Science Highlights
LBA 05 - Chemoradiotherapy (CRT) Followed By Consolidation Durvalumab (D) In Patients (pts) with Resectable or Borderline Resectable Stage IIB-IIIB NSCLC Who Become Unresectable during Neoadjuvant Treatment (Tx): Results from the Phase 2 MDT-Bridge Study
Presenter(s)
Andrea Filippi, MD - Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Lombardia